Management of Non-Muscle Invasive Bladder Cancer

This book covers the latest advances in non-muscle invasive bladder cancer care. It provides a review of the available evidence base for the efficacy of a range of therapeutic techniques, diagnostic procedures and risk factors.

Management of Non-Muscle Invasive Bladder Cancer features detailed guidance in uniformly formatted chapters on how to properly apply a range of available therapeutic treatments relevant for patient care. It is a valuable resource for all trainee and practising medical professionals who treat these patients.

Cover

Front Matter

  Part I. Background and Pathology on Bladder Cancer

 

1.  Background on Bladder Cancer

 

2.  Introduction to Bladder Cancer Type and Therapy

  Part II. Histological Variants in Bladder Cancer

 

3.  Histological Variants in Bladder Cancer—Sqaumous Cell Carcinoma and Squamous Differentiation

 

4.  Histological Variants in Bladder Cancer—Adenocarcinoma

 

5.  Histological Variants in Bladder Cancer—Sarcomatoid Differentiation

 

6.  Histological Variants in Bladder Cancer—Carcinosarcoma

 

7.  Histological Variants in Bladder Cancer—Small Cell Carcinoma

 

8.  Histological Variants—Plasmacytoid Bladder Cancer

  Part III. Epidemiology and Risk Factors in Bladder Cancer

 

9.  Introduction to Epidemiology of Bladder Cancer

 

10.  Epidemiology, Risk Factors and Occupational Hazards—A Systematic Review

 

11.  Systematic Review Results on Bladder Cancer Epidemiology, Occupational Hazards and Risk Factors

  Part IV. Assessment and Diagnostics in NMIBC

 

12.  Bladder Cancer—Diagnostic Pathways

 

13.  Systematic Review Method—Bladder Cancer Screening

 

14.  Bladder Cancer Screening—Systematic Review Results

 

15.  Bladder Cancer Screening Systematic Review Conclusion

 

16.  Statement of Main Findings and Specific Areas of Unmet Needs Arising from Systematic Review on Bladder Cancer Screening

 

17.  Usefulness of Screening in Bladder Cancer

  Part V. Techniques in Endoscopic Resection

 

18.  Management of Non-Muscle Invasive Bladder Cancer

 

19.  A New Technique—En Bloc Resection of Bladder Tumours

 

20.  Prognostic Factors for Endoscopic Resection in NMIBC

 

21.  NMIBC and Oncological Outcomes from Endoscopic Resection

 

22.  Recurrence in NMIBC

 

23.  Definitive Treatment in NMIBC

 

24.  A Systematic Review of En-Bloc Resection

 

25.  Systematic Review—Results from En-Bloc Resection of Bladder Cancer

  Part VI. Management of Low and Intermediate Risk Bladder Cancer

 

26.  NMIBC—Fulguration in Low Risk Disease

 

27.  Active Surveillance in Non-Muscle Invasive Bladder Cancer

 

28.  Hyperthermic MMC—A Systematic Review

 

29.  Literature Related to Hyperthermic MMC

  Part VII. Management of High Risk Non-Muscle Invasive Bladder Cancer

 

30.  BCG—Patterns of Administration

 

31.  NMIBC—BCG Strain and Outcomes

 

32.  Adverse Effects in BCG Therapy

 

33.  BCG and Elderly Patients

 

34.  A Systematic Review of NMIBC and Intravesical Chemotherapy

 

35.  A Systematic Review of NMIBC and Intravesical Chemotherapy—Results

 

36.  What the Literature Says Re BCG

 

37.  Prognostic Factors in BCG

 

38.  Intermediate and High Risk NMIBC and BCG

 

39.  NMIBC, Low Dose BCG and High-Risk Disease

 

40.  Alternatives to BCG Therapy—MMC

 

41.  BCG Versus Mitomycin C—A Systematic Review

 

42.  What the Literature Says NMIBC—BCG or MMC

 

43.  NMIBC and Intravesical Chemotherapy—HIVEC I and HIVEC II

 

44.  BCG Refractory Disease—Oncological Outcomes

 

45.  NMIBC—High Grade BCG Refractory Disease

 

46.  A Systematic Review on Alternatives in BCG Refractory Disease

 

47.  Systematic Review Results on BCG Refractory Disease Management

 

48.  What the Literature Says on BCG Refractory Disease and Alternatives

 

49.  NMIBC—BCG Refractory Disease and Use of Interferon

 

50.  Novel Agents in BCG Refractory Disease

 

51.  A Scoring System for Intravesical Therapy and NMIBC

 

52.  High Risk NMIBC and TURBT

 

53.  G3T1 Bladder Cancer: Cystectomy Versus BCG

 

54.  A Systematic Review of High-Grade Bladder Cancer—Methods

 

55.  Systematic Review of G3T1 Bladder Cancer

 

56.  Radical Cystectomy in High Grade NMI Bladder Cancer

  Part VIII. Bladder Cancer in the Elderly and Females

 

57.  Bladder Cancer in the Elderly

 

58.  Systematic Review on Bladder Cancer Management in Elderly Patients

 

59.  Systematic Review—Results on Bladder Cancer Management in the Elderly

 

60.  Reviews Relating to Management of Bladder Cancer in the Elderly

 

61.  Female Outcomes in Bladder Cancer

 

62.  A Systematic Review on Bladder Cancer and Female Gender

 

63.  Systematic Review Results on Bladder Cancer and Female Gender

 

64.  Reviews on Female Gender and Bladder Cancer

  Part IX. Bladder Cancer Survivorship

 

65.  Definition of Bladder Cancer Survivorship

 

66.  The Impact of Bladder Cancer Survivorship

 

67.  Unmet Needs in Bladder Cancer Survivorship

 

68.  Systematic Review—Bladder Cancer Survivorship—Unmet Needs

 

69.  Systematic Review Search Results—Bladder Cancer Survivorship and Unmet Need

 

70.  Survivorship Challenges in Non-Muscle Invasive Bladder Cancer

 

71.  Bladder Cancer Survivorship Care Plans

 

72.  Research Summary—A New Model of Care for Patients with Bladder Cancer (MODA)

 

73.  What Is the Impact of Sexual and Emotional Concerns on Patients Post Surgery for Patients with Bladder Cancer?

 

74.  Results—Telephone Interviews with Thematic Analyses

 

75.  Bladder Cancer Survivorship and Patient Reported Outcome Measures—Code 1 Erectile Dysfunction

 

76.  Bladder Cancer Survivorship and Patient Reported Outcome Measures—Code 2 Age Related Disease

 

77.  Bladder Cancer Survivorship and Patient Reported Outcome Measures—Code 3 Side Effects Post Operatively

 

78.  Bladder Cancer Survivorship and Patient Reported Outcome Measures—Code 4 Psychological Impact

 

79.  Bladder Cancer Survivorship and Patient Reported Outcome Measures—Code 5 Impact of Operation on General Health

 

80.  Bladder Cancer Survivorship Tool

 

81.  Health Related Quality of Life Measurements in Bladder Cancer Survivorship

 Back Matter